APA (7th ed.) Citation

Ma, J., Bai, Y., Liu, M., Jiao, T., Chen, Y., Yuan, B., . . . Yang, S. (2022). Pretreatment HDL‐C and ApoA1 are predictive biomarkers of progression‐free survival in patients with EGFR mutated advanced non‐small cell lung cancer treated with TKI. Thoracic Cancer, 13(8), 1126. https://doi.org/10.1111/1759-7714.14367

Chicago Style (17th ed.) Citation

Ma, Juan, et al. "Pretreatment HDL‐C and ApoA1 Are Predictive Biomarkers of Progression‐free Survival in Patients with EGFR Mutated Advanced Non‐small Cell Lung Cancer Treated with TKI." Thoracic Cancer 13, no. 8 (2022): 1126. https://doi.org/10.1111/1759-7714.14367.

MLA (9th ed.) Citation

Ma, Juan, et al. "Pretreatment HDL‐C and ApoA1 Are Predictive Biomarkers of Progression‐free Survival in Patients with EGFR Mutated Advanced Non‐small Cell Lung Cancer Treated with TKI." Thoracic Cancer, vol. 13, no. 8, 2022, p. 1126, https://doi.org/10.1111/1759-7714.14367.